{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:12:59Z","timestamp":1784819579406,"version":"3.55.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Circulating tumor DNA (ctDNA) sequence analysis shows great potential in the management of non-small cell lung cancer (NSCLC) and the prediction of drug sensitivity or resistance in many cancers. Here, we drew and compared the somatic mutational profile using ctDNA and tumor tissue sequence analysis in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), and assess its potential clinical value.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, 221 tumor tissues and 174 plasma samples from NSCLC patients were analyzed by hybridization capture-based next-generation sequencing (NGS) panel including 95 cancer-associated genes. Tumor response assessments were applied to 137 patients with advanced-stage (III and IV) NSCLC who first received targeted agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty significantly mutated genes were identified such as <jats:italic>TP53, EGFR, RB1, KRAS, PIK3CA, CD3EAP, CTNNB1, ERBB2, APC, BRAF, TERT, FBXW7<\/jats:italic>, and <jats:italic>HRAS<\/jats:italic>. Among them, <jats:italic>TP53<\/jats:italic> was the most frequently mutated gene and had a higher mutation probability in male (p = 0.00124) and smoking (p &amp;lt; 0.0001) patients. A total of 48.35% (191\/395) of NSCLC patients possessed at least one actionable alteration according to the OncoKB database. Although the sensitivity of genomic profiling from ctDNA was lower than that from tumor tissue DNA, the mutational landscape of target genes from ctDNA is similar to that from tumor tissue DNA, which led to 61.22% (30\/49) of mutational concordance in NSCLC. Additionally, the mutational concordance between tissue DNA and ctDNA in LUAD differs from that in LUSC, which is 63.83% versus 46.67%, indicating that NSCLC subtypes influence the specificity of mutation detection in plasma-derived ctDNA. Lastly, patients with <jats:italic>EGFR<\/jats:italic> and <jats:italic>TP53<\/jats:italic> co-alterations showed similar responses to Gefitinib and Icotinib, and the co-occurring <jats:italic>TP53<\/jats:italic> mutation was most likely to be a poor prognostic factor for patients receiving Gefitinib, indicating that the distributions and types of <jats:italic>TP53<\/jats:italic> mutations may contribute to the efficacy and prognosis of molecular targeted\u00a0therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>As a promising alternative for tumor genomic profiling, ctDNA analysis is more credible in LUAD than in LUSC. Genomic subtyping has strong potential in prognostication and therapeutic decision-making for NSCLC patients, which indicated the necessity for the utility of target NGS in guiding clinical management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.751106","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:33:39Z","timestamp":1645511619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Jun","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangman","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1757\/pgs.14.117","article-title":"Personalized Sequencing and the Future of Medicine: Discovery, Diagnosis and Defeat of Disease","volume":"15","author":"Esplin","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.6004\/jnccn.2010.0056","article-title":"Non-Small Cell Lung Cancer","volume":"8","author":"Ettinger","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid Biopsy: Monitoring Cancer-Genetics in the Blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer Heterogeneity: Implications for Targeted Therapeutics","volume":"108","author":"Fisher","year":"2013","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-294","article-title":"Detection of EGFR Mutations in Plasma and Biopsies From Non-Small Cell Lung Cancer Patients by Allele-Specific PCR Assays","volume":"14","author":"Weber","year":"2014","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature12625","article-title":"The Causes and Consequences of Genetic Heterogeneity in Cancer Evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"B9","article-title":"DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin From Apoptotic and Necrotic Cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1031","article-title":"Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy Versus Noninvasive Blood-Based Analyses","volume":"22","author":"Sundaresan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature12065","article-title":"Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of Circulating DNA and Protein Biomarkers to Predict the Clinical Activity of Regorafenib and Assess Prognosis in Patients With Metastatic Colorectal Cancer: A Retrospective, Exploratory Analysis of the CORRECT Trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/ncomms9760","article-title":"Multifocal Clonal Evolution Characterized Using Circulating Tumour DNA in a Case of Metastatic Breast Cancer","volume":"6","author":"Murtaza","year":"2015","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation Tracking in Circulating Tumor DNA Predicts Relapse in Early Breast Cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating Tumor DNA Analysis Detects Minimal Residual Disease and Predicts Recurrence in Patients With Stage II Colon Cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.06.021","article-title":"Circulating DNA is a non-Invasive Prognostic Factor for Survival in Non-Small Cell Lung Cancer","volume":"68","author":"van der Drift","year":"2010","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0400","article-title":"Circulating Cell-Free DNA in Plasma of Never Smokers With Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy","volume":"17","author":"Lee","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3063","article-title":"Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer From Never-Smokers: A Proof-of-Concept Study From BioCAST\/IFCT-1002","volume":"20","author":"Couraud","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer Statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.126","article-title":"Personalized Medicine in Lung Cancer: What We Need to Know","volume":"8","author":"Mok","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib Versus Cisplatin Plus Docetaxel in Patients With Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib Versus Cisplatin-Based Chemotherapy for EGFR Mutation-Positive Lung Adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of Overall Survival Data From Two Randomised, Phase 3 Trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.10.08","article-title":"Next Generation Sequencing Techniques in Liquid Biopsy: Focus on Non-Small Cell Lung Cancer Patients","volume":"5","author":"Malapelle","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.11.004","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper From","volume":"13","author":"Rolfo","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature13385","article-title":"Comprehensive Molecular Profiling of Lung Adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA From 21,807 Advanced Cancer Patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000355902","article-title":"Successes and Limitations of Targeted Cancer Therapy in Lung Cancer","volume":"41","author":"Suda","year":"2014","journal-title":"Prog Tumor Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0049","article-title":"Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Hong","year":"2018","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3990","article-title":"Evolution and Clinical Impact of Co-Occurring Genetic Alterations in Advanced-Stage EGFR-Mutant Lung Cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.011","article-title":"Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation With Clinical Outcomes","volume":"106","author":"VanderLaan","year":"2017","journal-title":"Lung Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated With First-Line Tyrosine Kinase Inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent Alterations in EGFR-Mutant Lung Cancers Associated With Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/358015a0","article-title":"Cancer. P53, Guardian of the Genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208615","article-title":"The P53 Pathway: Positive and Negative Feedback Loops","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.7.5626","article-title":"Stress-Dependent Changes in the Properties of P53 Complexes by the Alternative Translation Product P53\/47","volume":"7","author":"Powell","year":"2008","journal-title":"Cell Cycle"},{"key":"B40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cancers10090288","article-title":"P53 Isoforms and Their Implications in Cancer","volume":"10","author":"Vieler","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"Clusterprofiler: An R Package for Comparing Biological Themes Among Gene Clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-In-Human Phase 1 Study of the Anti-TIGIT Antibody Vibostolimab as Monotherapy or With Pembrolizumab for Advanced Solid Tumors, Including non-Small Cell Lung Cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"JCO2101323","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial","author":"Le","year":"2021","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib Monotherapy for Patients With Germline BRCA1\/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study","author":"Wu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0779-4","article-title":"Comprehensive Functional Annotation of Susceptibility Variants Identifies Genetic Heterogeneity Between Lung Adenocarcinoma and Squamous Cell Carcinoma","volume":"15","author":"Qin","year":"2021","journal-title":"Front Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.125","article-title":"Heterogeneity of ERBB2 Amplification in Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Undifferentiated Carcinoma of the Lung","volume":"25","author":"Grob","year":"2012","journal-title":"Mod Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)00114-8","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122","article-title":"Cancer Genome Landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2005.00653.x","article-title":"Molecular Analysis of the EGFR Gene in Astrocytic Gliomas: mRNA Expression, Quantitative-PCR Analysis of Non-Homogeneous Gene Amplification and DNA Sequence Alterations","volume":"31","author":"Arjona","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.62","article-title":"New Pattern of EGFR Amplification in Glioblastoma and the Relationship of Gene Copy Number With Gene Expression Profile","volume":"23","author":"Lopez-Gines","year":"2010","journal-title":"Mod Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.199","article-title":"Predictive Value of EGFR and HER2 Overexpression in Advanced non-Small-Cell Lung Cancer","volume":"28","author":"Hirsch","year":"2009","journal-title":"Oncogene"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv254","article-title":"Receptor Tyrosine Kinase Mutations in Developmental Syndromes and Cancer: Two Sides of the Same Coin","volume":"24","author":"McDonell","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2174\/1389450114666140106101412","article-title":"Targeting Tumor Suppressor P53 for Cancer Therapy: Strategies, Challenges and Opportunities","volume":"15","author":"Hong","year":"2014","journal-title":"Curr Drug Targets"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180926095709","article-title":"Role of P53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies","volume":"24","author":"Kaur","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1159\/000338790","article-title":"Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV non-Small Cell Lung Cancer Patients","volume":"85","author":"Zhao","year":"2013","journal-title":"Respiration"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13068","article-title":"Tumor Volume Determines the Feasibility of Cell-Free DNA Sequencing for Mutation Detection in Non-Small Cell Lung Cancer","volume":"107","author":"Ohira","year":"2016","journal-title":"Cancer Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive Molecular Characterization of Gastric Adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a Shared Vision for Cancer Genomic Data","volume":"375","author":"Grossman","year":"2016","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-13-0539","article-title":"Smoking, P53 Mutation, and Lung Cancer","volume":"12","author":"Gibbons","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0193802","DOI":"10.1371\/journal.pone.0193802","article-title":"Analytical Validation of a Next Generation Sequencing Liquid Biopsy Assay for High Sensitivity Broad Molecular Profiling","volume":"13","author":"Plagnol","year":"2018","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/LCTT.S147841","article-title":"Validation of Liquid Biopsy: Plasma Cell-Free DNA Testing in Clinical Management of Advanced Non-Small Cell Lung Cancer","volume":"9","author":"Veldore","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.critrevonc.2015.11.019","article-title":"TP53 and MDM2 Genetic Alterations in Non-Small Cell Lung Cancer: Evaluating Their Prognostic and Predictive Value","volume":"99","author":"Deben","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.06.014","article-title":"Prognostic and Predictive Effects of TP53 Co-Mutation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","volume":"111","author":"Labbe","year":"2017","journal-title":"Lung Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic Value of TP53 Concurrent Mutations for EGFR- TKIs and ALK-TKIs Based Targeted Therapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of Driver Mutations and Clinical Impact of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer: Analysis of Over 8000 Cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.751106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:33:51Z","timestamp":1645511631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.751106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":72,"alternative-id":["10.3389\/fonc.2021.751106"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.751106","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"article-number":"751106"}}